DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.
about
Practical aspects of NGS-based pathways analysis for personalized cancer science and medicineSomatic DNA mutation analysis in targeted therapy of solid tumoursNext-Generation Sequencing in Clinical Molecular Diagnostics of Cancer: Advantages and ChallengesPharmacogenomics in the clinicNext-generation sequencing to guide cancer therapyPredictive biomarkers in precision medicine and drug development against lung cancerTumor heterogeneity and resistance to EGFR-targeted therapy in advanced nonsmall cell lung cancer: challenges and perspectivesStructural, Biochemical, and Clinical Characterization of Epidermal Growth Factor Receptor (EGFR) Exon 20 Insertion Mutations in Lung CancerWhole-exome sequencing and clinical interpretation of formalin-fixed, paraffin-embedded tumor samples to guide precision cancer medicine.DoCM: a database of curated mutations in cancer.Mechanisms of Epidermal Growth Factor Receptor Tyrosine Kinase Inhibitor Resistance and Strategies to Overcome Resistance in Lung AdenocarcinomaOrganizing knowledge to enable personalization of medicine in cancerCIViC is a community knowledgebase for expert crowdsourcing the clinical interpretation of variants in cancerEGFR L858M/L861Q cis Mutations Confer Selective Sensitivity to Afatinib.Molecular fingerprinting of principal neurons in the rodent hippocampus: A neuroinformatics approach.Clinical analysis and interpretation of cancer genome dataEpidermal growth factor receptor (EGFR) mutations in lung cancer: preclinical and clinical data.Mutation based treatment recommendations from next generation sequencing data: a comparison of web toolsBeyond histology: translating tumor genotypes into clinically effective targeted therapies.The quest to overcome resistance to EGFR-targeted therapies in cancer.CVE: an R package for interactive variant prioritisation in precision oncology.EGFR variant heterogeneity in glioblastoma resolved through single-nucleus sequencing.Implementation of biomarker-driven cancer therapy: existing tools and remaining gaps.Impact of EGFR mutation detection methods on the efficacy of erlotinib in patients with advanced EGFR-wild type lung adenocarcinomaEmerging treatment for advanced lung cancer with EGFR mutation.MSEA: detection and quantification of mutation hotspots through mutation set enrichment analysisPower in numbers: meta-analysis to identify inhibitor-sensitive tumor genotypes.New approaches to targeted therapy in lung cancer.Translating genomic information into clinical medicine: lung cancer as a paradigm.DGIdb 2.0: mining clinically relevant drug-gene interactions.Evaluation of Three Small Molecular Drugs for Targeted Therapy to Treat Nonsmall Cell Lung Cancer.Compound EGFR mutation is frequently detected with co-mutations of actionable genes and associated with poor clinical outcome in lung adenocarcinoma.Rare EGFR exon 18 and exon 20 mutations in non-small-cell lung cancer on 10 117 patients: a multicentre observational study by the French ERMETIC-IFCT network.Standardized decision support in next generation sequencing reports of somatic cancer variants.The role of microRNAs in the regulation of apoptosis in lung cancer and its application in cancer treatmentClass act: safety comparison of approved tyrosine kinase inhibitors for non-small-cell lung carcinoma.mRNA-miRNA bipartite network reconstruction to predict prognostic module biomarkers in colorectal cancer stage differentiation.An update on genomic-guided therapies for pediatric solid tumors.Addressing epidermal growth factor receptor tyrosine kinase inhibitor resistance in non-small cell lung cancer.Towards precision medicine: discovering novel gynecological cancer biomarkers and pathways using linked data.
P2860
Q26748603-DCFC5BF4-31A8-44B2-8C51-D608A7049D6FQ26770324-2D0C020F-B5AD-4C99-8BBF-AC8F0EEA4BB9Q26782324-FF598906-1266-4B56-8463-D282E473F5FDQ26782786-BD0E9CE9-A0CC-471C-9E5D-5D6699DEE920Q26801946-3C6B9CC6-3B16-41A8-AA69-C9C1CD7263EDQ26824536-FB507A73-2B2D-4720-ADDD-89931F278576Q27014117-CAB24950-DAD1-4DEF-A100-AE5E96BE99B7Q27680966-BDF58E92-5F68-4438-BED7-2EE3FD4FA410Q27853005-1E9C60E6-68E3-4F0A-897F-D4DA87AE1A66Q27942768-8DBE44D1-FE98-4EBA-9B85-CDA8FDCC4717Q28069900-1CD11438-A615-4B7F-B44E-E08804C813F4Q28652806-8B12BB2B-1C6C-4A5E-BE8A-8F875E54B6B0Q29178984-A01BC188-B9A8-4CB5-85B9-B478FF48BDEFQ30397503-2499273D-42FA-4BBE-AB90-69A8A61F8178Q30491801-EE10C286-4E4A-40E4-A3E8-DCA53611F0C5Q30617093-D4205DB0-8FB9-482F-8EAB-701785066D65Q30850656-51A05F84-A45E-405F-85CC-D7DC185DF672Q31058925-90F357EE-1C83-4F3F-B855-3D20F11F750FQ33560928-B36D4243-768D-4A4D-BC85-E37008161B40Q33725976-B4772CD8-5379-4A12-90E0-030C6E20DE78Q33730180-07E2D1A9-0EAB-49AB-AD8E-71D88B9A88A0Q34016908-83290D58-2109-4A2D-98C5-31C674681E90Q34163458-0E589771-35C4-4499-A88E-82B271AA83F6Q34172448-A75B9F1E-712A-438A-B9CC-5E6D465C73F0Q34483953-5944E939-B0A9-438B-B89D-3F98FD6E27F6Q34484638-C75AA5E6-65D3-4316-B63B-C85CED0844FEQ35082587-43FE6223-3401-4C2A-906F-03B04E0D505EQ35984001-483DA524-08CD-4C90-ACB3-DE519A693D9AQ36354845-345A7550-8480-48F3-9E48-41894B6F25C9Q36434749-348E835C-363C-49AE-9F04-DA059F269252Q36705603-D0FA8F74-EC4C-4978-AA3C-A663010701A9Q36844350-1D58669A-460D-4AE5-B64E-48A6BA415A85Q37404105-4CC52EAE-0C3D-4075-9BD3-1C221B6340B5Q38207312-E6B8F456-69FF-4E4F-B861-309A31E8C085Q38226821-B9F526D1-D336-4555-BD1F-0DD514A29EFCQ38262804-190551D3-13B8-4872-A32B-798E78F11B50Q38598443-D540CEEC-544F-4677-AFCB-863AEAE58165Q38673827-CA2D5FB5-8421-4C51-B65B-073D1F34AEC6Q38766913-80912280-7AAB-49F9-9FE0-3764768A2559Q41714473-A4CC1EF1-F57C-466D-8B26-109AE492FD07
P2860
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment (DIRECT): a catalog of clinically relevant cancer mutations to enable genome-directed anticancer therapy.
description
2013 nî lūn-bûn
@nan
2013 թուականի Յունուարին հրատարակուած գիտական յօդուած
@hyw
2013 թվականի հունվարին հրատարակված գիտական հոդված
@hy
2013年の論文
@ja
2013年論文
@yue
2013年論文
@zh-hant
2013年論文
@zh-hk
2013年論文
@zh-mo
2013年論文
@zh-tw
2013年论文
@wuu
name
DNA-Mutation Inventory to Refi ...... e-directed anticancer therapy.
@ast
DNA-Mutation Inventory to Refi ...... e-directed anticancer therapy.
@en
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment
@nl
type
label
DNA-Mutation Inventory to Refi ...... e-directed anticancer therapy.
@ast
DNA-Mutation Inventory to Refi ...... e-directed anticancer therapy.
@en
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment
@nl
prefLabel
DNA-Mutation Inventory to Refi ...... e-directed anticancer therapy.
@ast
DNA-Mutation Inventory to Refi ...... e-directed anticancer therapy.
@en
DNA-Mutation Inventory to Refine and Enhance Cancer Treatment
@nl
P2093
P2860
P1476
DNA-Mutation Inventory to Refi ...... e-directed anticancer therapy.
@en
P2093
Heidi Chen
Jenny Andrews
Leora Horn
Riyad Naser
P2860
P304
P356
10.1158/1078-0432.CCR-12-1894
P407
P50
P577
2013-01-23T00:00:00Z